Endothelial Microvesicles: A Plasma Biomarker of Futile Recanalization Post Intravenous Thrombolysis in Patients with Stroke

Technical Summary: Endothelial Microvesicles as Biomarkers for Futile Recanalization in Acute Ischemic Stroke

Problem Statement
Despite the efficacy of intravenous recombinant tissue plasminogen activator (rtPA) for acute ischemic stroke (AIS), a significant proportion of patients experience "futile recanalization." This condition is defined as the successful restoration of blood flow (vascular recanalization) without corresponding clinical neurological improvement. Current methods for assessing recanalization, such as transcranial Doppler (TCD), digital subtraction angiography, and CT angiography, have limitations including potential risks (radiation, renal impairment) and an inability to fully predict clinical prognosis. There is a critical need for personalized, blood-based biomarkers that can evaluate thrombolytic efficacy and endothelial health to guide subsequent treatment decisions, such as endovascular thrombectomy.

Methodology
This prospective, single-center study was conducted at the Affiliated Hospital of Guangdong Medical University (China) between December 2021 and December 2023.

• Participants: The study enrolled 195 patients with AIS who received rtPA therapy within 4.5 hours of symptom onset.
• Biomarker Analysis: Plasma endothelial microvesicles (EMVs) were isolated via density gradient centrifugation and quantified using fluorescence nanoparticle tracking analysis (NTA). EMV identity was confirmed via transmission electron microscopy (TEM) and Western blotting for Annexin V.
• Timepoints: Blood samples were collected at three intervals: baseline (pre-rtPA), 24 hours post-rtPA, and 90 days post-rtPA.
• Outcome Definitions:
  • Early Futile Recanalization: Defined as complete recanalization (TIBI grade 4–5 on TCD) with no neurological improvement (NIHSS reduction <4 points) at 24 hours.
  • Late Futile Recanalization: Defined as complete recanalization (TIBI grade 4–5) with a poor functional outcome (modified Rankin Scale [mRS] score ≥2) at 90 days.
• Statistical Analysis: The study utilized ROC curve analysis to determine the diagnostic value (AUC) of EMV levels. Multivariate logistic regression was employed to assess independent associations, adjusting for confounders such as age, NIHSS score, ASPECTS, and lipid profiles.

Key Results

• Association with Futile Recanalization: Plasma EMV levels at both baseline and 24 hours were positively correlated with both early and late futile recanalization.
  • Early Futile Recanalization: Patients in this group exhibited significantly higher EMV levels at baseline (3.67±1.36 vs. 2.79±1.05, p<0.001) and 24 hours (5.47±2.59 vs. 4.21±1.78, p=0.001) compared to those with successful recanalization.
  • Late Futile Recanalization: EMV levels at 24 hours and 90 days were significantly elevated in the late futile group compared to the late recanalization group. Notably, in the late recanalization group, EMV levels decreased significantly by day 90, whereas they remained elevated in the futile group.
• Diagnostic Performance:
  • For early futile recanalization, the AUCs for baseline and 24-hour EMVs were 0.70 and 0.67, respectively, outperforming the NIHSS score alone (AUC 0.58).
  • For late futile recanalization, the AUCs were 0.52 (baseline) and 0.66 (24 hours).
  • A combined model of baseline EMVs, 24-hour EMVs, and the NIHSS score yielded the highest diagnostic efficacy (AUC 0.69 for late futile recanalization).
• Correlations with Severity and Subtypes: EMV levels were positively correlated with stroke severity (NIHSS score), infarct volume, and poor functional outcomes (mRS). Specifically, patients with large artery atherosclerosis (LAA) subtypes and moderate-to-large infarcts demonstrated significantly higher EMV levels compared to other subtypes or smaller infarcts.

Significance and Claims
The authors claim that plasma EMVs serve as a surrogate indicator for futile recanalization following rtPA administration in acute ischemic stroke. The study posits that elevated EMV levels reflect endothelial cell (EC) dysfunction, which contributes to poor collateral circulation, microvascular injury, and compromised brain autoregulation—mechanisms underlying futile recanalization.

The paper suggests that measuring EMVs could provide a more personalized assessment of thrombolytic efficacy than imaging alone. Specifically, the authors propose that:

1. Baseline EMVs may effectively predict short-term (early) futile recanalization.
2. 24-hour EMVs show greater potential as a marker for predicting late futile recanalization.
3. Clinical Utility: In resource-constrained settings where advanced neuroimaging is unavailable, a combined model of EMVs and the NIHSS score offers a low-cost, rapid alternative to guide clinical decision-making. Patients with high EMV levels and elevated NIHSS scores might be prioritized for urgent vascular intervention or intensive monitoring, while those with favorable profiles might avoid unnecessary aggressive strategies.

The authors conclude that integrating molecular biomarkers like EMVs into routine clinical assessments could pave the way for more precise and individualized stroke management, though they acknowledge limitations regarding the single-center design and the need for larger, multicenter validation.